Available online on 15.09.2024 at ijmspr.com

 International Journal of Medical Sciences and Pharma Research 

Open Access to Medical Science and Pharma Research

Copyright  © 2024 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access                                                                                                                                                                                                                                             Review Article

 

Mitigating the Impact of HIV on Organ Function: Blood Transfusions as a Therapeutic Strategy

*Emmanuel Ifeanyi Obeagu 

Department of Medical Laboratory Science, Kampala International University, Uganda

 

 

Introduction

HIV (Human Immunodeficiency Virus) remains a major global health challenge, with an estimated 38 million people living with the virus worldwide. Despite advancements in antiretroviral therapy (ART), which have transformed HIV from a fatal disease to a manageable chronic condition, the virus continues to exert a significant impact on various organ systems. HIV infection is associated with a range of complications, including cardiovascular disease, renal dysfunction, hepatic impairment, and pulmonary issues, which can dramatically affect the health and quality of life of those living with the virus. As the understanding of HIV-related complications evolves, it becomes increasingly important to explore effective therapeutic strategies aimed at mitigating these effects.^1-2 One of the most common complications associated with HIV is anemia, a condition characterized by low hemoglobin levels that can lead to fatigue, weakness, and decreased exercise capacity. Anemia can arise from various factors in HIV-positive individuals, including chronic inflammation, opportunistic infections, and the side effects of ART. Addressing anemia is crucial, as it can significantly impair organ function and overall health. Blood transfusions have traditionally been used to manage severe anemia, but their role in the context of HIV-related organ dysfunction is gaining recognition as a potential therapeutic strategy.^3-4 The impact of HIV on organ function is multifaceted and involves complex interactions between the virus, the immune system, and the host's physiological responses. In particular, the direct effects of HIV on endothelial cells and immune dysregulation contribute to increased cardiovascular risk and the development of HIV-associated nephropathy. Additionally, chronic inflammation associated with HIV can lead to liver dysfunction and metabolic syndrome, further complicating the health of individuals living with the virus.⁵ Blood transfusions can play a vital role in mitigating the impact of HIV on organ function by restoring hemoglobin levels, enhancing oxygen delivery, and improving overall tissue perfusion. The physiological benefits of transfusions extend beyond merely addressing anemia; they can also promote better oxygenation of organs, thereby supporting cellular metabolism and function. Improved organ perfusion is particularly crucial for organs with high metabolic demands, such as the heart and kidneys, where oxygen delivery is essential for maintaining function and preventing further complications.⁶

In addition to correcting anemia, blood transfusions may have immunomodulatory effects that can benefit individuals with HIV. Research suggests that transfusions can enhance the function of immune cells and improve inflammatory responses, potentially reducing the risk of infections and other complications. This immune modulation is especially important in the context of HIV, where chronic immune activation and dysregulation can lead to increased susceptibility to opportunistic infections and other health challenges.⁷ Clinical evidence supporting the use of blood transfusions in HIV-positive individuals is accumulating, demonstrating improvements in hemoglobin levels, quality of life, and organ function. Studies have shown that patients receiving blood transfusions often experience enhanced energy levels, improved functional capacity, and a reduction in symptoms associated with anemia. Furthermore, there is growing recognition of the need for individualized approaches to transfusion therapy, taking into account each patient’s unique clinical circumstances and comorbidities.^8-9 Despite the potential benefits of blood transfusions, several challenges and considerations must be addressed. Risks associated with transfusion therapy, including allergic reactions, infection transmission, and iron overload, necessitate careful monitoring and adherence to established transfusion protocols. Additionally, the integration of blood transfusions with ongoing ART is critical for optimizing patient care and maximizing the therapeutic benefits of both interventions.¹⁰ A comprehensive care approach is essential for effectively integrating blood transfusions into the management of organ function in HIV-positive individuals. This approach involves collaboration among various healthcare providers, including infectious disease specialists, hematologists, and primary care physicians, to develop individualized treatment plans that address the multifaceted needs of patients. Holistic assessments that consider nutritional status, comorbid conditions, and psychosocial factors are vital for optimizing treatment outcomes.^11-12

The Impact of HIV on Organ Function

HIV (Human Immunodeficiency Virus) infection has far-reaching effects on the body, impacting multiple organ systems and leading to various complications that can significantly compromise health and quality of life. The following sections outline the impact of HIV on several key organ systems, including the cardiovascular, renal, hepatic, and pulmonary systems. HIV is associated with an increased risk of cardiovascular disease (CVD), including myocardial infarction, stroke, and heart failure.  HIV infection leads to persistent immune activation and inflammation, contributing to endothelial dysfunction and accelerated atherosclerosis. Elevated levels of inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), are often observed in HIV-positive individuals. HIV and certain antiretroviral therapies (ART) can induce metabolic abnormalities, including lipid dysregulation and insulin resistance. These changes further increase the risk of CVD, as they are associated with the development of metabolic syndrome. HIV can directly infect cardiovascular tissues, leading to structural and functional changes that compromise heart function. The virus may also affect vascular endothelial cells, contributing to impaired vasodilation and increased vascular stiffness.^13-15

HIV-associated nephropathy (HIVAN) is a significant complication in HIV-positive individuals, particularly among those of African descent.  The virus can directly infect renal epithelial cells, particularly podocytes, leading to cellular injury and the development of focal segmental glomerulosclerosis (FSGS). This damage results in proteinuria and progressive renal impairment. Inflammation plays a central role in the pathogenesis of HIVAN. Increased levels of pro-inflammatory cytokines and immune activation contribute to renal damage and dysfunction. The presence of co-infections, such as hepatitis C and cytomegalovirus (CMV), can further exacerbate renal impairment in HIV-positive individuals. As renal function declines, patients may experience complications such as fluid overload, electrolyte imbalances, and anemia, all of which can further impact overall health.^16-17 The liver is another organ that can be adversely affected by HIV infection.  Many individuals living with HIV are also co-infected with hepatitis B (HBV) or hepatitis C (HCV). These co-infections can lead to liver inflammation, fibrosis, and cirrhosis, significantly impacting hepatic function. Some antiretroviral medications have hepatotoxic potential, which can contribute to elevated liver enzymes and impaired liver function. Regular monitoring of liver function is essential for individuals on ART. HIV-positive individuals often experience metabolic syndrome, which can lead to non-alcoholic fatty liver disease (NAFLD). This condition is characterized by the accumulation of fat in the liver and can progress to steatohepatitis and fibrosis.^18-19

Liver dysfunction can have systemic implications, affecting drug metabolism, increasing the risk of bleeding due to coagulopathy, and exacerbating other health issues. HIV infection can significantly impact pulmonary function, increasing the risk of respiratory complications. Individuals with HIV have a higher risk of opportunistic infections, such as pneumonia, tuberculosis, and fungal infections. These infections can lead to acute respiratory distress and long-term pulmonary complications. HIV is associated with an increased risk of pulmonary arterial hypertension (PAH), a condition characterized by elevated blood pressure in the pulmonary arteries. This can lead to right heart failure and decreased exercise tolerance. The inflammatory processes associated with HIV can contribute to airway hyperreactivity and chronic obstructive pulmonary disease (COPD). Individuals with HIV are at an increased risk of developing these conditions, further compromising lung function.^20-21 The cumulative impact of HIV on multiple organ systems can lead to significant morbidity and mortality. As organ function declines, individuals may experience a range of symptoms, including fatigue, weakness, cognitive impairment, and decreased quality of life. Addressing the effects of HIV on organ function is crucial for optimizing patient care. Effective management strategies that target both HIV and its associated complications can improve health outcomes and enhance the quality of life for individuals living with the virus.²²

The Role of Blood Transfusions

Blood transfusions play a critical role in the management of various complications associated with HIV, particularly in addressing anemia and improving overall organ function. As individuals living with HIV often experience a range of hematological issues, transfusions can provide significant therapeutic benefits. HIV-related inflammation can lead to anemia of chronic disease, characterized by the body’s inability to utilize iron effectively due to inflammation. Infections such as tuberculosis and cytomegalovirus can contribute to anemia, either directly or through inflammatory responses. Some Antiretroviral Therapy (ART) regimens can induce bone marrow suppression, leading to reduced erythropoiesis and subsequent anemia. Blood transfusions are effective in rapidly correcting anemia, restoring hemoglobin levels, and alleviating symptoms associated with low oxygen-carrying capacity, such as fatigue and weakness. Improved hemoglobin levels lead to enhanced oxygen delivery to vital organs, which is essential for maintaining their function and preventing further complications.^23-24

Adequate oxygenation is crucial for the proper functioning of organs, especially those with high metabolic demands, such as the heart, brain, and kidneys. 

Transfusions provide a direct increase in hemoglobin concentration, improving the blood's capacity to carry oxygen. This effect is particularly beneficial for organs at risk of hypoxia due to anemia. Enhanced oxygen delivery supports cellular metabolism, promoting optimal organ function and reducing the risk of ischemic damage. This is especially critical in patients with existing organ dysfunction or those undergoing surgical interventions.²⁵ Research suggests that blood transfusions can improve the functionality of immune cells, such as T lymphocytes and macrophages, which play vital roles in combating infections. This enhancement can help mitigate the immune dysregulation often observed in HIV-positive individuals. Transfusions may help modulate inflammatory responses by balancing pro-inflammatory and anti-inflammatory cytokines. By reducing chronic inflammation, transfusions can potentially decrease the risk of opportunistic infections and improve overall immune health.^26-27

Wound healing is a critical aspect of recovery for individuals living with HIV, particularly those undergoing surgical procedures or experiencing trauma. Enhanced oxygen delivery to wounded tissues is essential for cellular proliferation, collagen synthesis, and angiogenesis—key processes in wound healing. Transfusions also deliver essential nutrients and growth factors, supporting the healing process and reducing the risk of complications such as infections and delayed healing. Patients receiving blood transfusions often report increased energy levels, improved functional capacity, and enhanced quality of life. These improvements can directly impact their ability to adhere to ART and engage in daily activities. Clinical evidence suggests that blood transfusions may contribute to better cardiovascular, renal, and hepatic function by enhancing oxygen delivery and reducing the burden of anemia. Patients who receive timely blood transfusions may experience fewer complications related to anemia, leading to improved health outcomes and reduced hospitalizations.^28-29 The decision to administer blood transfusions should be based on a thorough assessment of the patient's clinical situation, including the severity of anemia, overall health status, and presence of comorbid conditions. Potential risks associated with blood transfusions, such as transfusion reactions, infection transmission, and iron overload, necessitate careful monitoring and adherence to established transfusion protocols. Coordinating blood transfusions with ongoing ART is crucial for optimizing patient care and maximizing the therapeutic benefits of both interventions.³⁰

Challenges and Considerations

While blood transfusions can provide significant benefits for individuals living with HIV, several challenges and considerations must be addressed to ensure safe and effective use. These challenges encompass clinical, logistical, and ethical dimensions that healthcare providers must navigate to optimize patient outcomes. Patients may experience allergic reactions, febrile non-hemolytic reactions, or, in rare cases, hemolytic reactions due to ABO incompatibility or other blood group antigen mismatches. These reactions can range from mild to severe and require careful monitoring. Although rigorous screening and testing of blood products have significantly reduced the risk of transfusion-transmitted infections (TTIs), there remains a small risk of transmitting pathogens such as HIV, hepatitis B, hepatitis C, and bacterial infections. This risk is particularly concerning for immunocompromised individuals. Repeated blood transfusions can lead to iron overload, which can cause damage to vital organs, including the heart, liver, and pancreas. Monitoring iron levels and implementing chelation therapy when necessary is essential to prevent complications.^31-32

The decision to administer blood transfusions should be based on a comprehensive assessment of each patient’s clinical situation.  Assessing the degree of anemia and its impact on the patient’s overall health and quality of life is crucial. Transfusions may be warranted in cases of severe anemia or symptomatic patients, while mild anemia may be managed with other interventions. Patients with multiple comorbidities may have different transfusion needs and risks. A thorough evaluation of underlying health conditions, including cardiovascular, renal, and hepatic function, is necessary to determine the appropriateness of transfusion therapy. Engaging patients in the decision-making process regarding transfusions are essential. Patients should be informed about the benefits and risks, enabling them to make informed choices about their treatment options.^33-34 Some ART regimens may interact with medications used to manage transfusion reactions or complications. Monitoring for drug interactions is essential to avoid adverse effects. Patients with anemia may struggle with adherence to ART due to fatigue and other symptoms. Improving hemoglobin levels through transfusions can enhance overall well-being and support better adherence to HIV treatment. Careful timing of blood transfusions in relation to ART administration is necessary to maximize therapeutic benefits and minimize potential complications. Ensuring a steady supply of safe and compatible blood products can be a challenge, especially in low-resource environments. Ongoing efforts to promote blood donation and improve transfusion services are crucial. Adequate infrastructure for transfusion services, including trained personnel, monitoring equipment, and protocols for managing transfusions, is essential for ensuring patient safety. Disparities in access to healthcare can affect the timely availability of transfusion therapy for individuals living with HIV. Addressing barriers to care is vital for improving health outcomes.^35-37 Patients must be fully informed about the risks and benefits of blood transfusions, enabling them to provide informed consent. This process should include discussions about alternatives and potential complications. Ensuring equitable access to transfusion therapy for all individuals, regardless of socioeconomic status or geographical location, is essential. Healthcare providers must advocate for policies that promote fair access to lifesaving treatments. Respecting patient autonomy and individual preferences is paramount in the decision-making process regarding blood transfusions. Healthcare providers should facilitate discussions that allow patients to voice their concerns and preferences.³⁸

Integrating Blood Transfusions into Comprehensive Care

The integration of blood transfusions into the comprehensive care of individuals living with HIV is essential for optimizing health outcomes and enhancing quality of life. As HIV infection can lead to various complications, including anemia and organ dysfunction, blood transfusions can play a critical role in addressing these issues. A thorough and holistic assessment of patients living with HIV is vital for determining the need for blood transfusions and developing individualized care plans.  Healthcare providers should conduct comprehensive clinical evaluations to identify the presence and severity of anemia, assess organ function, and determine the overall health status of the patient. This evaluation should consider factors such as hemoglobin levels, comorbid conditions, and symptomatology. Many individuals with HIV may experience nutritional deficiencies that contribute to anemia and impaired organ function. Evaluating the patient’s nutritional status, including micronutrient deficiencies (e.g., iron, vitamin B12, folate), is essential for guiding interventions and optimizing transfusion therapy.³⁹ Assessing the psychosocial factors affecting patients, including mental health, social support, and adherence to ART, is crucial.⁴⁰ 

Implementing coordinated care strategies is essential for ensuring that blood transfusions are administered safely and effectively.  Developing standardized care pathways that outline the criteria for blood transfusions, monitoring protocols, and follow-up care can help streamline the process and ensure consistency in patient management. Effective communication among healthcare team members is crucial for ensuring that all aspects of a patient’s care are addressed. Regular case reviews and interdisciplinary meetings can facilitate information sharing and collaborative decision-making.  Educating patients about the rationale for blood transfusions, potential benefits, and associated risks is essential for promoting informed decision-making and adherence to treatment plans. Empowering patients with knowledge can enhance their engagement in their own care. Regular assessments of hemoglobin levels, organ function, and overall health status following transfusions are necessary to evaluate the effectiveness of the intervention and identify any complications. Patients may require long-term management of anemia or other complications related to HIV. Developing individualized follow-up plans that address ongoing needs, including nutritional support and monitoring for iron overload, is essential for optimizing health outcomes. Comprehensive care plans should be flexible and adaptable to the evolving needs of patients. Regular reassessment of the patient’s clinical status and treatment response allows for timely adjustments to care strategies.^41-43

Conclusion

The integration of blood transfusions into the management of individuals living with HIV represents a promising therapeutic strategy for addressing the complications associated with the virus, particularly anemia and its impact on organ function. As HIV continues to affect millions worldwide, understanding the multifaceted effects of the virus on health and exploring effective interventions are crucial for improving patient outcomes. Blood transfusions provide significant benefits, including correcting anemia, enhancing oxygen delivery, and potentially modulating immune responses, all of which contribute to improved organ function and overall quality of life.

However, the implementation of transfusion therapy is not without challenges. Healthcare providers must navigate the risks associated with transfusions, including potential complications and the need for individualized patient assessments. A holistic approach that encompasses comprehensive evaluations, multidisciplinary collaboration, and coordinated care strategies is essential for optimizing the use of blood transfusions in this population. By fostering effective communication among healthcare teams and ensuring patient education, providers can empower individuals living with HIV to make informed decisions about their care.

References

1. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50

2. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45

3. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

4. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024;103(2): e36937. https://doi.org/10.1097/MD.0000000000036937 PMid:38215133 PMCid:PMC10783375

5. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. The Journal of infectious diseases. 2002;185(Supplement_2): S110-114. https://doi.org/10.1086/340198 PMid:12001031

6. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739. https://doi.org/10.3389/fmed.2022.903739 PMid:36186804 PMCid:PMC9519983

7. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24. https://doi.org/10.22270/ijmspr.v10i2.95

8. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. https://doi.org/10.22270/ajdhs.v3i2.39

9. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood, The Journal of the American Society of Hematology. 2019;133(17):1854-1864. https://doi.org/10.1182/blood-2018-11-833996 PMid:30808637

10. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.

11. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).

12. Heron SE, Elahi S. HIV infection and compromised mucosal immunity: oral manifestations and systemic inflammation. Frontiers in immunology. 2017; 8:241. https://doi.org/10.3389/fimmu.2017.00241 PMid:28326084 PMCid:PMC5339276

13. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41

14. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

15. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64

16. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16

17. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfusion medicine reviews. 2012;26(2):164-180. https://doi.org/10.1016/j.tmrv.2011.07.006 PMid:21872426 PMCid:PMC3668661

18. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32

19. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36

20. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. Journal of Allergy and Clinical immunology. 2005;115(6):1119-1128. https://doi.org/10.1016/j.jaci.2005.04.036 PMid:15940121

21. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51. https://doi.org/10.22270/ijmspr.v10i2.102

22. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26

23. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117

24. Lotfi R, Kaltenmeier C, Lotze MT, Bergmann C. Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfusion Medicine and Hemotherapy. 2016 Mar 8;43(2):120-32. https://doi.org/10.1159/000444941 PMid:27226794 PMCid:PMC4872058

25. Cunha PP, Minogue E, Krause LC, Hess RM, Bargiela D, Wadsworth BJ, Barbieri L, Brombach C, Foskolou IP, Bogeski I, Velica P. Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy. Elife. 2023;12: e84280. https://doi.org/10.7554/eLife.84280 PMid:37166103 PMCid:PMC10229120

26. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

27. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35

28. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019;11(3):200. https://doi.org/10.3390/v11030200 PMid:30818749 PMCid:PMC6466530

29. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59

30. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57

31. Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S. Chronic illness burden and quality of life in an aging HIV population. AIDS care. 2013;25(4):451-458. https://doi.org/10.1080/09540121.2012.712669 PMid:22894702 PMCid:PMC3535557

32. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15

33. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72

34. Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. The Lancet Haematology. 2020;7(12):e892-901. https://doi.org/10.1016/S2352-3026(20)30292-1 PMid:33242446

35. Hébert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. Jama. 2003;289(15):1941-1949. https://doi.org/10.1001/jama.289.15.1941 PMid:12697796

36. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood, The Journal of the American Society of Hematology. 2009;113(15):3406-3417. https://doi.org/10.1182/blood-2008-10-167643 PMid:19188662

37. Kaur P, Basu S. Transfusion-transmitted infections: existing and emerging pathogens. Journal of postgraduate medicine. 2005;51(2):146-151.

38. Wiersum-Osselton JC, Whitaker B, Grey S, Land K, Perez G, Rajbhandary S, Andrzejewski C, Bolton-Maggs P, Lucero H, Renaudier P, Robillard P. Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study. The Lancet Haematology. 2019;6(7):e350-358. https://doi.org/10.1016/S2352-3026(19)30080-8 PMid:31080132

39. Smit-Sibinga C, Pitman JP. Transmission of HIV through blood-how to bridge the knowledge gap. InHIV and AIDS-Updates on biology, immunology, epidemiology and treatment strategies 2011: 583-618. InTech, Rijeka, Croatia. https://doi.org/10.5772/19618 PMCid:PMC3157305

40. Slonim AD, Bish EK, Xie RS. Red blood cell transfusion safety: probabilistic risk assessment and cost/benefits of risk reduction strategies. Annals of Operations Research. 2014; 221:377-406. https://doi.org/10.1007/s10479-011-0925-0

41. Steffen KM, Spinella PC, Holdsworth LM, Ford MA, Lee GM, Asch SM, Proctor EK, Doctor A. Factors influencing implementation of blood transfusion recommendations in pediatric critical care units. Frontiers in Pediatrics. 2021; 9:800461. https://doi.org/10.3389/fped.2021.800461 PMid:34976903 PMCid:PMC8718763

42. Barro L, Drew VJ, Poda GG, Tagny CT, El‐Ekiaby M, Owusu‐Ofori S, Burnouf T. Blood transfusion in sub‐Saharan Africa: understanding the missing gap and responding to present and future challenges. Vox Sanguinis. 2018;113(8):726-736. https://doi.org/10.1111/vox.12705 PMid:30221365

43. Ako S, Njunda LA, Akum EA, Benjamin PT, Assob J. Hematological related disorders and transfusion of HIV patients on highly active antiretroviral therapy (HAART) in the South West Region of Cameroon: hematological monitory parameters for HIV follow-up. J HIV Retrovirus. 2018;4(1):5